Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9650411 | 0.68 | ACHE (0.34) | — | |
| SCHEMBL4806936 | 0.67 | ACHE (0.35) | NPC1RAB9A | |
| SCHEMBL2492357 | 0.65 | MAPT (0.67) | KDM4ENPC1ALDH1A1TP53RAB9A | |
| SCHEMBL4804521 | 0.62 | LMNA (0.35) | KDM4ENPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL409332 | 0.62 | MAPT (0.76) | KDM4ENPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL4809916 | 0.61 | MAPK1 (0.38) | KDM4ENPC1ALDH1A1RAB9AHSD17B10 | |
| Hydrochloric Acid SCHEMBL2860788 | 0.61 | MAPT (0.73) | KDM4ENPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL4013103 | 0.59 | ALDH1A1 (0.41) | KDM4ENPC1ALDH1A1TP53RAB9A | |
| SCHEMBL20209584 | 0.59 | MAPT (0.55) | KDM4ENPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL18866853 | 0.58 | MAPT (0.53) | KDM4EALDH1A1HSD17B10MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465808-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-16 | — | — | US | disclosed |
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| EP-1641762-A2 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| US-20060014817-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
| EP-1525190-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005005393-A2 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004007463-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014817-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | KDM4E 3601/4885NPC1 1873/4885ALDH1A1 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.